

PRODUCED WITH CARE

THE UPJOHN COMPANY

KALAMAZOO, MICHIGAN 49001
TELEPHONE (616) 345-8571

J. C. GAUNTLETT
Vice President
and Director

January 28, 1969

Dear Doctor:


Because of misleading and possibly misunderstood statements which have appeared in the lay press, we would like to take this opportunity to clarify our position and to assure you that Panalba remains available.

In the Federal Register of December 24, 1968, the Food and Drug Administration published a notice about Panalba and certain other combination antibiotics. The question is whether certain combinations of drugs should be allowed to remain on the market.

Approximately 40% of the drugs prescribed today are combinations of one form or another. In principle, if the physician's right to prescribe is denied for one category of useful drugs, it is conceivable this same right may be denied for others. We believe the decision as to whether these drugs are used should rest in the hands of the practicing physician.

In accordance with the Federal Register, all interested persons who may be adversely affected by removal of these drugs from the market are invited to comment. Correspondence should be directed to Dr. Paul Bryan, Special Assistant for Drug Efficacy Study Implementation, Bureau of Medicine, Food and Drug Administration, 200 C Street S.W., Washington, D.C., 20204. If you elect to write to Dr. Paul Bryan we, too, would appreciate a copy of your correspondence.

Sincerely,



J. C. Gauntlett

JJS

*I have written to the
F.D.A. and they have
asked for the product
information. I have
sent it to them. I
will be glad to
provide you with a
copy of the letter
I wrote to the F.D.A.
if you wish.*